drugset
drugset / Trial / NCT03591887

A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

NCT03591887 ↗

Phase 2 Completed 108 enrolled Affibody TFS Trial Form Support · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This randomized, double-blinded dose-finding study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis. The study consists of 52-week Core study and two optional 52-week periods, Extension and Prolongation of Extension. The Core study consists of three periods: Induction (placebo-controlled, Week 0-12), Optimization (Week 12-24), and Individualization (Week 24-52).

Timeline

Start
2018-03-07
Primary completion
2019-03-27
Completion
2021-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Izokibep Protein / enzyme biologic 2 mg Subcutaneous
Subject Izokibep Protein / enzyme biologic 20 mg Subcutaneous
Subject Izokibep Protein / enzyme biologic 80 mg Subcutaneous
Subject Izokibep Protein / enzyme biologic 160 mg Subcutaneous

Indications

psoriasis